Intrinsic (innate) and acquired (adaptive) resistance to chemotherapy critically limits the outcome of cancer treatments. For many years, it was assumed that the interaction of a drug with its molecular target would yield a lethal lesion, and that determinants of intrinsic drug resistance should therefore be sought either at the target level (quantitative changes or/and mutations) or upstream of this interaction, in drug metabolism or drug transport mechanisms. It is now apparent that independent of the factors above, cellular responses to a molecular lesion can determine the outcome of therapy. This review will focus on programmed cell death (apoptosis) and on survival pathways (Bcl-2, Apaf-1, AKT, NF-jB) involved in multidrug resistance. We will present our molecular interaction mapping conventions to summarize the AKT and IjB/NF-jB networks. They complement the p53, Chk2 and c-Abl maps published recently. We will also introduce the 'permissive apoptosis-resistance' model for the selection of multidrug-resistant cells.
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General mechanisms of chemotherapy resistance and implication of apoptosis
Key questions for molecular oncologists, clinicians and patients are 'what are the mechanisms of intrinsic or acquired drug resistance in solid tumors, and how might they be circumvented?' Intrinsic drug resistance, evident from the first course of therapy, is the rule for melanomas, lung and pancreatic cancers (Soengas and Lowe, 2003) . Acquired drug resistance, arising during the course of treatment, is common in relapsing leukemia, ovarian and breast carcinomas and seems to involve similar mechanisms to those of intrinsic resistance ( Figure 1 ).
Much progress has been made in understanding cellular responses to standard DNA-damaging chemotherapeutic agents in vitro. For many years, it was assumed that the interaction of a drug with its molecular target would yield a lethal lesion, and that determinants of intrinsic drug resistance should therefore be sought either at the target level (quantitative changes or/and mutations) (Brangi et al., 1999) or upstream of this interaction, in drug metabolism or drug transport mechanisms. In fact, active efflux of drugs is among the best characterized mechanisms of multidrugresistance (Gottesman, 2002) . Host factors independent of the tumor (e.g. rapid elimination from the host circulation) could also explain inter-individual differences in response to standard regimens. Pharmacokinetic and pharmacogenomic analyses of the host are aimed at defining the role of such parameters in order to optimize treatment (Desai et al., 2003) .
It is now apparent that independent of the factors above, downstream cellular responses to a given DNA lesion can determine the outcome of therapy. Therapeutically beneficial responses can include necrosis, mitotic catastrophe, apoptosis or prolonged cell cycle arrest. For example, two competing p53-mediated responses to cytotoxics can be observed in vitro, namely cell death or cell cycle arrest (Waldman et al., 1997; elDeiry, 1998; Bunz et al., 1999) . Abrogation of arrest by knockout of key checkpoint regulators (e.g. p53, p21/ WAF1 or 14-3-3s) enhances the cell death response to a subset of DNA-damaging agents (Gupta et al., 1997; Waldman et al., 1997; Chan et al., 1999; Chan et al., 2000; Han et al., 2002) . On the other hand, in the presence of intact checkpoints, cell death may be mediated via the mitochondrial apoptotic pathway (elDeiry, 1998; Bartke et al., 2001 ) in a p53-dependent manner. Indeed, cancer cells rendered null for p53 are resistant to mitochondrial-mediated apoptosis induced by 5-fluorouracil (Bunz et al., 1999) .
The mitochondrial apoptotic pathway is in turn regulated by members of the Bcl-2 family (Gross et al., 1999; Kroemer, 1999) including proapoptotic p53 transcriptional targets like Bax, Bak, Noxa, and PUMA (Bartke et al., 2001; Ryan et al., 2001; Yu et al., 2001) and antiapoptotic members like Bcl-2 and Bcl-x L (for a review, see Sordet et al., 2003) . The relative ratio of proto antiapoptotic members determines a threshold for induction of apoptosis (Zha et al., 1997; Korsmeyer, 1999; Kroemer, 1999; Reed, 1999; Huang and Strasser, 2000; Lutz, 2000; Cheng et al., 2001 ). Thus, Bax-null cells are resistant to mitochondria-mediated apoptosis Schmitt and Lowe, 2002) , and overexpression of exogenous Bcl-x L or Bcl-2 suppresses apoptosis (Schott et al., 1995; Walczak et al., 2000; Chipuk et al., 2001) . On the other hand, downregulation of Bcl-x L or Bcl-2 can enhance the apoptotic response to DNA damage, but in a p53-and Bax-dependent manner (Hayward et al., 2003) .
Lessons from original models
Experimental evidence that downstream apoptotic responses determine therapeutic outcomes in vivo has recently been provided by Lowe and co-workers using the Em-myc transgenic murine model of B-cell lymphoma (Schmitt et al., 2002a; Schmitt and Lowe, 2002) . They also demonstrated that drug-induced senescence can result in prolonged disease stability while providing a residual pool of viable malignant cells from which late relapsing clones may ultimately emerge. These studies have mapped out new challenges and new opportunities for the oncologist of the future. They illustrate many conceptual points relevant throughout the rest of our review.
An early paper in the series demonstrated conclusively that overexpression of the antiapoptotic protein Bcl-2 produces a multidrug resistance phenotype in primary lymphomas in vivo (Schmitt et al., 2000) . Subsequent work demonstrated that on a p53 þ /À heterozygote background, Bcl-2 overexpression completely suppressed the selective pressure for loss of p53 during lymphomagenesis (Schmitt et al., 2002a) , and that the resulting p53 þ /À tumors retained chromosomal stability. This remarkable finding indicates that, in this setting, genetic instability in p53-null tumors is merely a bystander effect. It is the proapoptotic functions of p53 that drive selective pressure for p53 loss during lymphomagenesis.
Bcl-2 overexpressing p53 þ /À lymphomas differ dramatically from p53-null lymphomas in their response to therapy (Schmitt et al., 2002b) . Overexpression of Bcl-2 in p53-null tumors makes no difference to response or survival with rapid relapse and death the rule. Overexpression of Bcl-2 on a p53 þ /À background has a profound effect. The immediate response to therapy is no longer observed nor do the tumors rapidly progress. The disease enters a stable state resembling cellular senescence and lasting many weeks but ultimately terminating in a lethal late relapse. The cooperative interaction of wildtype p53 with p16 INK4a was identified as a critical genetic determinant of drug-induced senescence. Thus, the effect of one genetic lesion (Bcl-2 overexpression) depends critically on the status of another (the p53 background). Therefore it is clear that the mechanisms of intrinsic drug resistance, and the acquisition of new resistance mechanisms upon relapse, are profoundly influenced by the tumorigenic pathway giving rise to the primary disease.
The cellular response to a given lesion depends critically on the cellular genotype and on the integrity of a complex network of interacting response pathways downstream of the drug-induced lesion. In addition, different upstream lesions, induced by different classes of chemotherapeutic drugs, may invoke overlapping responses in the downstream networks. Therefore, intrinsic or acquired genetic alterations in components of these networks, arising during carcinogenesis or during treatment, can produce cross-resistance to different classes of chemotherapeutic agents. This extremely important clinical problem is an underlying cause of treatment failure for many cancer patients.
What are the opportunities and challenges? The work of Lowe et al. has demonstrated two separate bystander effects (genetic instability in p53-null cells and in cells with INK4a loss, Schmitt et al., 2002a ) each of which is not selected for during lymphomagenesis, but each of which influences therapy (in these cases producing resistance). Precisely because such bystander effects are unselected, it might be hoped that at a different locus, or under different therapy, similar bystander effects might instead give rise to enhanced sensitivity and an exploitable therapeutic opportunity. In any event, it is clear that a detailed understanding of the genetic status of a given tumor will provide an opportunity to optimize primary therapy. But how can we characterize the genetic status of a given tumor? Do genomic lesions need to be characterized in detail or will expression profiles be adequate in practice? Encouragement has recently come from childhood acute lymphoblastic leukemia (Yeoh et al., 2002) , where a finite number of different forms of the disease can be defined at the level of gene expression. But, as always, the devil is in the detail. Even in their well-defined murine lymphoma model discussed above (Schmitt et al., 2002a; Schmitt and Lowe, 2002) , Lowe and co-workers frequently encountered genetic heterogeneity in the resulting lymphomas. It seems probable that advanced malignant solid tumors in humans will harbor multiple genetically different subclones and indeed chemotherapeutic genotoxic agents, which induce genomic instability and mutations, may even contribute to the development of drug-resistant cancer cells during the course of treatment (Cox, 2001) . The task of the clinician charged with matching therapy to each subclone in a single patient will be formidable indeed.
In this review, we will focus on selected apoptotic response networks, which exemplify some of the Apoptosis defects and chemotherapy resistance Y Pommier et al challenges and opportunities outlined above. A complementary review detailing the p53, Chk2 and c-Abl networks was recently published (Sordet et al., 2003) . We will use the molecular interaction mapping approach recently developed in our laboratory and designed to synthesize a large volume of diverse information. Several vital conceptual points are immediately yielded by our attempt at synthesis. There are a great complexity of interactions, extensive positive or negative feedback controls, and potential for highly nonlinear responses to a given set of stimuli. These aspects of cellular response offer formidable hurdles to quantitative understanding, but they also raise the following hopes. Perhaps it is precisely the nonlinearity of cellular response that yields an exploitable therapeutic ratio for current chemotherapeutic agents. If we could understand the networks better and thus identify the optimum genetic context in which to use a given class of agent, perhaps we could exploit this therapeutic opportunity more effectively. Our review, and the molecular interaction maps that underpin it, are aimed at this goal.
Mitochondrial and plasma membrane receptor pathways and chemotherapeutic response
The mitochondrial 'intrinsic' pathway and the transmembrane 'extrinsic' pathway are the two principal pathways leading to apoptosis, both of which converge on caspases, a family of cysteine proteases. Caspases are divided in two groups: initiator and effector caspases. Initiator caspases are activated as they bind to adaptator molecules; after which, they activate effector caspases. The initiator caspase for the mitochondrial pathway is caspase-9 (and possibly caspase-2), whereas the initiator caspases for the transmembrane pathway are caspases 8 and 10. Both pathways share the effector caspases (caspases-3, -6 and -7).
The mitochondrial 'intrinsic' pathway
Most chemotherapeutic drugs induce mitochondrial membrane permeabilization as they induce apoptosis. This event is under the control of the Bcl-2 proteins family. Permeabilization of the outer mitochondrial membrane induces the leakage of proapoptotic molecules including cytochrome c, Smac/DIABLO, HtrA2/ Omi, apoptosis inducing factor (AIF) and endonuclease G (Endo G) from the mitochondrial intermembrane space (Ravagnan et al., 2002) . AIF and Endo G directly induce nuclear modifications, whereas cytochrome c, Smac/Diablo and HtrA2/Omi promote caspase activation. In the cytosol, cytochrome c induces the oligomerization of apoptosis protease activating factor-1 (Apaf-1) in the presence of ATP or dATP (Li et al., 1997; Hu et al., 1999) . Apaf-1 oligomers recruit procaspase-9 molecules in a complex called the 'apoptosome' where juxtaposition of procaspase-9 molecules results in autoactivation Saleh et al., 1999) . The release of mature caspase-9 activates additional caspase-9 molecules as well as caspase-3 and -7. In turn, caspase-3 activates downstream caspase cascades (Slee et al., 1999) . At the same time, the release of Smac/ DIABLO and HtrA2/Omi neutralize the inhibitory effect of inhibitors of apoptosis proteins (IAPs) on caspase-3, -7 and -9 (Deveraux et al., 1999; Vaux and Silke, 2003) . At least in response to DNA-damaging agents, caspase-2 could play a role upstream of the mitochondria, but the mechanism of its activation remains only partially known (Lassus et al., 2002) .
The transmembrane 'extrinsic' pathway
In some cell types, apoptotic response to chemotherapeutic drugs implicates the death receptor Fas (APO-1/ CD95). Crosslinking of Fas by its natural ligand (FasL) induces clustering of Fas, which in turn recruits FADD (Chinnaiyan et al., 1995) and procaspase-8 (Medema et al., 1997) to form a complex known as the deathinducing signaling complex (DISC). Oligomerization of procaspase-8 in the DISC autoactivates and releases mature caspase-8 (Salvesen and Dixit, 1999) . Depending on the cell type, activated caspase-8 induces apoptosis by two different signaling pathways (Scaffidi et al., 1998) . In type I cells, large amounts of active caspase-8 formed at the DISC induce direct cleavage/activation of procaspase-3 independently of mitochondria. In type II cells, very little DISC and small amounts of active caspase-8 are insufficient to activate procaspase-3 directly. Instead, caspase-8 cleaves the 'BH3-only protein' Bid, generating an active fragment (tBid) that activates the mitochondrial death pathway Luo et al., 1998) . Various anticancer drugs can activate the death receptor pathway by enhancing the expression of Fas and FasL (Sordet et al., 2003) . At least in some cell types, this upregulation is transcriptiondependent and implicates p53 (Muller et al., 1998) . Interaction of FasL with Fas at the cell surface defines an autocrine/paracrine pathway similar to that observed in activation-induced cell death in T lymphocytes. However, the role of FasL in drug-induced apoptosis is probably not essential because apoptosis is not suppressed by antagonist antibodies or molecules that prevent FasL interaction with Fas (Micheau et al., 1997) . Anticancer drugs can also induce Fas clustering at the cell surface of tumor cells in the absence of FasL (Micheau et al., 1999; Shao et al., 2001) . Lipid rafts at the plasma membrane could be involved in this process (Lai, 2003) . However, apoptosis induced by chemotherapeutic drugs is not altered in embryonic fibroblasts from FADD (Yeh et al., 1998) and caspase-8 (Varfolomeev et al., 1998) knockout mice, indicating only a partial role for the death receptor pathway in response to chemotherapeutic agents.
Role of the Bcl-2 protein family at the mitochondrial level
The human Bcl-2 family includes more than 30 anti-and proapoptotic molecules that bind to each other and form homo-and heterodimers (Reed, 2002; Tsujimoto, 2003) . These proteins are characterized by the presence of one to four conserved Bcl-2 homology (BH) domains (BH1 to BH4). The antiapoptotic members include Bcl-2, Bcl-x L , Bcl-w, Mcl-1, Bfl-1 (A1), and Boo (Diva). They possess sequence homology within three or four BH domains. They are primarily localized to the mitochondrial outer membrane where they prevent the release of cytochrome c and other proapoptotic proteins from the mitochondria to the cytosol and the nucleus.
The proapoptotic Bcl-2 family is divided into two groups. The multidomain proapoptotic group, comprising Bax, Bak, Mtd (Bok), and Bcl-rambo, share sequence homology among the BH1, BH2, and BH3 domains. The still growing 'BH3-only proteins' comprises Bad, Bid, Noxa, Puma, Bik (Nbk), Bim (Bod), Hrk (DP5), Blk, Bmf, Bnip3 (nix), Bnip3L, p193, and Bcl-G. The two subfamilies of proapoptotic members are functionally distinct. BH3-only proteins act as sensors of cellular damage and initiate the death process. The multi-BH domain proteins Bax and Bak probably act downstream of the BH3-only proteins, as Bax/Bakdouble knockout cells are resistant to ectopic expression of the BH3-only proteins tBid or Bim Wei et al., 2001) . In healthy cells, most BH3-only proteins (Bad, Bid, Bim and Bmf) are localized to extramitochondrial places. Upon specific cellular damage, these proteins undergo post-translational modifications and relocate to mitochondria (Puthalakath and Strasser, 2002) . For example, Bid is cleaved/ activated by caspase-8, Bad is dephosphorylated, dissociates from cytosolic 14-3-3 scaffold proteins and binds/inactivates Bcl-2 and Bcl-x L (see Figure 3b) , and Bim and Bmf detach from elements of the cytoskeleton. Also, other BH3-only proteins such as Noxa and Puma are synthesized in response to DNA damage after transcriptional activation by p53 (see review by Norbury and Zhivotovsky in this issue).
BH3-only proteins induce mitochondrial permeabilization either by inhibiting the Bcl-2-related antiapoptotic proteins or by activating proapoptotic proteins of the Bax/Bak subfamily (Bouillet and Strasser, 2002) . In healthy cells, Bax is present in the cytoplasm, possibly sequestered by 14-3-3 proteins (Nomura et al., 2003) , whereas Bak is anchored to the outer mitochondrial membrane. Upon apoptotic stimulation, Bax is relocalized from the cytoplasm to the mitochondria and forms homomultimer/complex, possibly with Bak, that trigger permeabilization of the outer mitochondrial membrane Antonsson et al., 2001) . The molecular mechanisms involved in mitochondrial membrane permeabilization and the role of Bcl-2 proteins in regulating these mechanisms remain a matter of debate (Debatin et al., 2002; Bettaieb et al., 2003) .
Bcl-2 protein family deregulation in cancer
Bcl-2 overexpression was initially described in follicular lymphomas as a consequence of a t(14;18) translocation, and as a poor prognostic marker in acute myelogenous leukemia (AML) and non-Hodgkin's lymphomas. Overexpression of Bcl-2 was subsequently described in prostate, breast and colon carcinomas, as well as glioblastomas. Overexpression of Mcl-1, another antiapoptotic, Bcl-2-related protein, was identified in relapsed AML, and was associated with poor prognosis. Other changes in Bcl-2-related protein expression identified in cancer cells include different mutations in the Bax gene, and changes in the proapoptotic to antiapoptotic Bcl-2 protein ratio .
Bcl-2 protein family and chemoresistance
Overexpression of Bcl-2 prevents apoptosis induced by most and chemotherapeutic drugs, including alkylating agents, and topoisomerase inhibitors (Kamesaki et al., 1993; Walton et al., 1993) . Also, fibroblasts deficient in both Bax and Bak are resistant to apoptosis induced by various agents that induce mitochondrial stress . However, fibroblasts with single deficiency for either Bax or Bak are not significantly defective for apoptosis induced by these agents, suggesting that both Bax and Bak proteins may be functionally redundant ). This apparent redundancy may be cell type-dependent as Bax-deficient HCT116 cells are resistant to apoptosis induced by staurosporine (Theodorakis et al., 2002) . A number of anticancer agents, such as arsenic and lonidamine, can directly permeabilize the outer membrane of mitochondria, at least in vitro, and overexpression of Bcl-2 prevents arsenic-and (Larochette et al., 1999; Ravagnan et al., 1999; Sordet et al., 2001; Solary et al., 2003) . Based on the role of Bcl-2 proteins in regulating mitochondrial membrane permeabilization, and their frequently modified expression in human cancers, Bcl-2 proteins are legitimate targets (antiapoptotic members) or prototypes (proapoptotic members) for inducing apoptosis either by themselves or in association with other anticancer drugs. However, molecular markers should be used when using Bcl-2-targeted therapies since not all the apoptosis-resistant cells overexpress Bcl-2, as demonstrated in the breast cancer cell lines from the NCI cell screen (Nieves-Neira and Pommier, 1999).
Bcl-2 protein family as targets for cancer chemotherapy
Various strategies inhibit Bcl-2 and related Bcl-2 proteins (Reed, 2002) . The most advanced approach utilizes an antisense oligonucleotide designed to downregulate the Bcl-2 expression (Genasense or G3139; Genta-Aventis). Genasense has broad anticancer activities in preclinical models. Phase III clinical trials are currently in progress in chronic lymphocytic leukemia, acute myelocytic leukemia, multiple myeloma, malignant melanoma and non-small-cell lung cancer (www.genta.-com) . A bi-specific antisense Bcl-2/ Bcl-x L has also shown efficacy in inducing apoptosis in tumor cells that overexpress both Bcl-2 and Bcl-x L (Hopkins-Donaldson et al., 2003; Jiang et al., 2003) . Recently, an antisense targeting Mcl-1 was suggested to be more potent than an antisense targeting Bcl-2 for chemosensitizing myeloma cells (Derenne et al., 2002) .
As previously discussed, BH3-only proteins induce mitochondrial membrane permeabilization by binding to and neutralizing the prosurvival Bcl-2 proteins. Based on these observations, small molecules that interact with the surface pocket of Bcl-2 (also called BH3 mimetic) are being developed. HA-14-1 interacts with Bcl-2 and induces apoptosis of tumor cells (Wang et al., 2000) . Antimycin A binds to the BH3-binding domain of Bcl-2 and Bcl-x L , thereby permeabilizing purified mitochondria expressing Bcl-x L (Tzung et al., 2001) . Another strategy is to develop peptidic BH3 mimetics corresponding to the BH3 domain of Bax or Bcl-2 fused to the antennapedia plasma membrane translocation domain (Ant) to facilitate cellular penetration. These molecules induce mitochondrial permeabilization via a In response to survival signals, p110 and p85 are both targeted to the plasma membrane where the stimulatory binding of p85 to p110 is favoured (#3, B2): Alternatively, PI3K can be activated by binding of p110 to Ras (when Ras is bound to GTP) (Vivanco and Sawyers, 2002) . (#4, B3-4): PI3K catalyse the phosphorylation of phosphatidylinositol (PtdIns) phosphates leading to the conversion of PtdIns(4,5)P 2 (PIP 2 ) into PtdIns(3,4,5)P 3 (PIP 3 ). PIP 3 activates a variety of downstream effectors, including AKT. (#5; D4): To be active, AKT requires phosphorylation of Thr308 in the activation loop. However, AKT can exist in an inactive form, due intramolecular binding of its N-terminal plextrin homology (PH) domain to the activation loop in the kinase domain. This intramolecular binding masks Thr308 and prevents its phosphorylation. (#6; D4): Alternatively, the PH domain of AKT can bind PIP 3 on the plasma membrane, thereby disrupting the intramolecular bond and making Thr308 accessible for phosphorylation. Targeting AKT to the plasma membrane activates AKT constitutively because AKT's activating kinases are located at the plasma membrane (Andjelkovic et al., 1999; Datta et al., 1999; Vivanco and Sawyers, 2002) . (#7; E4): PDK1 efficiently phosphorylates AKT on Thr308. (#8; D3): PDK1 is constitutively active and bound to the plasma membrane by way of a PH domain (Datta et al., 1999) . (#9; D3): The contingency arrow denotes the dual requirement for both AKT and PDK1 to be membrane-bound in order for Thr308 phosphorylation of AKT to take place. (#10; E4): AKT is further activated by phosphorylation at Ser473. (#11; E3): The responsible kinase (sometimes designated PDK2) has not been clearly identified, but may form a complex with PDK1 (Datta et al., 1999) . The requirement for Thr308 phosphorylation (#12; D5) and the enhancing activity by Ser473 phosphorylation (#13; D5) are indicated by the contingency arrows. (#14; D4): The mutual inhibition between Thr308 phosphorylation and intramolecular binding is indicated by contingency symbol. (#15; E4): The Ser473 residue of AKT can also be phosphorylated by integrin-linked kinase (ILK). ILK can be stimulated by integrins (#16; D1), and by growth-factor receptors (#17; D1). ILK-induced phosphorylation of Ser473 is required for AKT activity, at least in some cells (Troussard et al., 2003) . This mechanism may explain how anchorage-and growth factor-dependent survival (anti-apoptotic) signals are transmitted to AKT. (#18; C2): ILK, like AKT and PDK1, is membrane-bound through a PH domain. The colocalization of these molecules at the plasma membrane, where the integrins and growth-factor receptors are located, facilitates their interactions. Activated AKT dissociates from the plasma membrane and translocates to the cytoplasm and nucleus (Datta et al., 1999) . (#19, E4): Activated AKT is rapidly dephosphorylated by protein phosphatase 2A (PP2A); Ser473 being a better substrate than Thr308 (Andjelkovic et al., 1999) . (#20; B3): PTEN (phosphatase and tensin homologue deleted on chromosome 10), an inositol 5 0 -phosphatase converts PIP 3 back to PIP 2 (Stambolic et al., 1998) . (#21; B5): The SHIP phosphatases (SHIP1 and SHIP2) also act on PIP 3 to generate PIP 2 , but remove phosphate from the 5-position rather than from the 3-position (Damen et al., 1996; Wisniewski et al., 1999) . (#22; E5): CTMP binds to the carboxyl-terminal regulatory domain of AKT and inhibits phosphorylation on Ser473, and to a lesser extent Thr308 (Maira et al., 2001) . (#23; D3): HSP90 binds to the kinase domain of AKT and prevents PP2A-dependent dephosphorylation of AKT . (#24; D2): HSP90 can also bind to the kinase domain of PDK1 and prevents proteasome-dependent degradation of PDK1 (Fujita et al., 2002) . (#25; E6): The contingency arrow indicates that HSP90-AKT and HSP90-PDK1 complexes enhance the AKT activity. (#26; E1): Geldanamycin decreases the AKT activity by binding to HSP90 and suppressing the HSP90-PDK1 interaction. The direct effect of geldanamycin on the AKT kinase activity is not well defined as geldanamycin does not inhibit the binding of HSP90 to AKT (Fujita et al., 2002) . (b) Molecular interaction map for Bad inactivation by AKT and PKA protein kinases and for Bad activation by Cdk1 and PP2A. In nonapoptotic cells, Bad is inactive, associated with 14-3-3 proteins, which leaves Bcl-2 and Bcl-x L free to act as antiapoptotic factors. AKT inactivates Bad by promoting its binding to 14-3-3 after phosphorylation of Bad at serine 136. Binding of Bad to 14-3-3 produces a conformational change in Bad, which enables Bad phosphorylation by protein kinase A (PKA) at serine 155. This phosphorylation permanently disrupts the Bad-Bcl-2 and Bad-Bcl-x L complexes. In apoptotic cells, Bad associates with Bcl-2 and Bcl-x L in response to dephosphorylation of serine 155 by the protein phosphatase PP2A or in response to Bad phosphorylation at serine 128 by the Cdk1 : cyclin B (or A) protein kinase. When molecular species have been implicated in favoring or suppressing apoptosis, their symbols are bordered in red and green respectively(for a recent review, see Hermeking, 2003) " Apoptosis defects and chemotherapy resistance Y Pommier et al mechanism that is not inhibited by Bcl-2 or Bcl-x L (Vieira et al., 2002) , suggesting that they might be useful to overcome multidrug resistance in tumor cells that overexpress Bcl-2-related antiapoptotic proteins.
Apaf-1 and the apoptosome
As discussed above, Apaf-1 is an adaptor molecule that binds to and promotes procaspase-9 activation in the presence of cytochrome c. The complex 'Apaf-1 : procaspase-9 : cytochrome c' is known as an 'apoptosome'.
Tumor cells can develop various strategies to prevent the formation of apoptosomes and thereby procaspase-9 activation. The APAF-1 gene is frequently hypermethylated and therefore silenced in melanoma cells (Soengas et al., 2001) , and human leukemia (Fu et al., 2003) . Also, the heat shock proteins (HSPs) HSP27, HSP70 and HSP90 can prevent procaspase-9 activation at the apoptosome level. HSP27 binds to cytochrome c and prevents cytochrome-c-mediated interaction of Apaf-1 with procaspase-9 (Bruey et al., 2000) , whereas HSP70 and HSP90 bind to Apaf-1 and prevent Apaf-1 oligomerization, thereby preventing the activation of procaspase-9 (Beere et al., 2000; Pandey et al., 2000; Saleh et al., 2000) . As HSP27, HSP70 and HSP90 are overexpressed in various cancers as well as in response to cellular stresses, including those generated by cytotoxic drugs (Sarto et al., 2000; Parcellier et al., 2003) , HSPs might be involved in resistance to anticancer therapy by preventing the apoptosome formation. Lastly, procaspase-9 is phosphorylated/inactivated by AKT, which itself is activated in various tumor cells (see the section on AKT and Figure 3b ). These observations suggest that combination of specific HSP inhibitors (such as geldanamycin, and its derivative 17-AAG) and/ or AKT inhibitors with existing anticancer drugs should have synergistic effects.
Conventions for molecular interaction maps
The increasing complexity of the cellular pathways implicated in cellular responses led us to develop molecular interactions maps (Kohn, 1999 (Kohn, , 2001 Kohn et al., 2004 ; http://discover.nci.nih.gov). The conventions used in these maps are summarized in Figure 2 ( Kohn, 1999) . In these maps, coordinates are used for locating specific molecular interactions (e.g., in Figure 3 , the p110 subunit of PI3K is located at coordinates C3). Annotation describing molecular interactions will be referred in the text as # followed by the coordinates in italics. For instance, in Figure 3 (#6, D4) refers to annotation #6 (described in the caption) located at coordinate D4 on the map.
Molecular alterations in the Akt and NF-jB survival pathways associated with defective apoptotic responses to chemotherapy
We recently published molecular interactions of p53, cAbl and Chk2, and their impact on apoptotic response (Sordet et al., 2003) . Here, we will focus on two other pathways regulated by serine/threonine kinases of known relevance to apoptosis regulation: AKT (also known as protein kinase B (PKB)) and the IkB kinase (IKK) complex. Figures 3 and 4 summarize the molecular interaction maps for AKT and IkB/NF-kB, respectively. Mutations in these pathways are frequent in human cancers, demonstrating their dual role in sustaining tumor growth (carcinogenic potential) and in producing resistance to chemotherapy. Understanding these alterations offers novel opportunities for developing therapeutic strategy against cancers.
AKT
AKT is the cellular homolog of the retroviral oncogene v-Akt. The AKT family comprises three members (AKT1, AKT2 and AKT3), which, in general, are broadly expressed (Vivanco and Sawyers, 2002) . AKT is activated by phosphatidylinositol 3-phosphate (PIP 3 ), which is produced by PI(3)kinases (PI3K). As schematized in Figure 3 (#1; C3), PI3K heterodimers contain both a catalytic (p110) and a regulatory (p85) subunit. PI3K catalyses the phosphorylation of inositol lipids at the D3 position of the inositol ring (#4; B4). The resulting PIP 3 activates a variety of downstream effectors, including AKT (#9; D4-5). For example, in response to survival factors such as hematopoietic growth factors (e.g., IL-3), AKT is recruited to the plasma membrane by its binding to PIP 3 , and is activated by sequential phosphorylation on Thr308 by PDK1 (phosphoinositide-dependent protein kinase-1) (#7; E4-5) and on Ser473 by PDK2 (#10; E4-5) or ILK (#15; E4-5) (Datta et al., 1999; Hill and Hemmings, 2002; Vivanco and Sawyers, 2002; Troussard et al., 2003) . AKT is negatively regulated by the lipid phosphatases PTEN (#20; B3), SHIP-1 and SHIP-2 (#21; B5), which prevent AKT activation by decreasing PIP 3 levels (Damen et al., 1996; Stambolic et al., 1998; Wisniewski et al., 1999) . Also, the protein phosphatase 2A (PP2A) inactivates AKT directly by dephosphorylating Ser473 and Thr308 (#19; E4 & F4); Ser473 being a better substrate than Thr308 (Andjelkovic et al., 1999) . Carboxyl-terminal modulator protein (CTMP) binds to the carboxyl-terminal regulatory domain of AKT at the plasma membrane and reduces the activity of AKT by inhibiting phosphorylation on Ser473 and to a lesser extent Thr308 (#22; E5 & F5) (Maira et al., 2001) . Conversely, HSP90 maintains the AKT activity by binding to AKT (#23; D3) and by preventing PP2A-dependent dephosphorylation of AKT . HSP90 also prevents proteasome-dependent degradation of PDK1 (#24; D2) (Fujita et al., 2002) . AKT is therefore regulated by a complex network of phosphorylation/dephosphorylation reactions, which can be concisely summarized using the molecular interaction mapping shown in Figure 3 .
The downstream targets of AKT regulate apoptosis, cell cycle, DNA repair, nitric oxide production and glycogen metabolism (Vivanco and Sawyers, 2002) . AKT protects cells from apoptosis by phosphorylating and inactivating several key apoptotic molecules: Bad, procaspase-9 and FKHR1 (Figure 3a, C6) . The molecular details of Bad regulation are summarized in Figure 3b . Bad phosphorylation by AKT (at serine 136) inactivates Bad by inducing its interaction with 14-3-3 proteins (reviewed in Hermeking, 2003) . This binding induces a conformational change in Bad, which allows binding and phosphorylation of Bad by PKA (at serine 155). This phosphorylation permanently disrupts the Bad-Bcl-2 and Bad-Bcl-x L complexes. Bcl-2 and Bcl-x L , are then free to act as antiapoptotic effectors (Blume-Jensen et al., 1998). The 14-3-3 proteins also serve as adaptors/effectors for AKT-mediated FKHR1 inactivation. Similar to the case of Bad, phosphorylation of FKHR1, a member of the Forkhead family of transcription factors, induces the binding of FKHR1 to 14-3-3 proteins in the cytosol and prevents the nuclear import of FKHR1. As a consequence, AKT inhibits the FKHR1-mediated transactivation of the proapoptotic genes Bim and FasL . Phosphorylation of procaspase-9 (at Ser196) prevents its activation in the apoptosome (Cardone et al., 1998) . AKT also inactivates p53 by phosphorylating Mdm2 on Ser166 and Ser186, which increases Mdm2's ability to translocate to the nucleus where it binds to p53 and promotes p53 degradation (for a review, see Sordet et al., 2003) . Finally, AKT activates NF-kB by Figure 4 Molecular interaction map of NF-kB/IkB (the numbers that follow # refer to interactions on the map; letter-number combinations in italics are map coordinates). (#1; B4 and #2; B5): The Rel/NF-kB transcription factor family comprises several structurally related proteins. The p50 and p52 subunits of NF-kB1 and NF-kB2 are derived from p100 and p105 precursors by post-transcriptional proteolytic processing that involves addition of a single ubiquitin molecule. The ubiquitination enzymes have not been clearly identified (Karin and Ben-Neriah, 2000) . (#3; C4): Members of the NFkB proteins can form homodimers or heterodimers, the most prominent and ubiquitous consists of the p65RelA : p50 heterodimer. In most cells, these complexes exist in a latent, inactive form in the cytoplasm where they are bound to IkB inhibitor proteins that mask their nuclear localization signals (NLS) (#7; C3). (#4; D4 and #5; F4): Upon degradation of IkB's in response to various stimuli, the NLS on the p65 : p50 heterodimer is exposed, which leads to NF-kB nuclear translocation and binding to specific DNA sequences (referred to as the kB sites (F4)). (#6; F5): NF-kB then activates the transcription of a number of genes whose products inhibit apoptosis: Bcl-x L and Bfl1/A1, cIAPs, c-FLIP, TRAF-1 and TRAF-2, A20, IEX-1L and MnSOD (references cited by Bharti and Aggarwal, 2002; . NF-kB also induces transcription of three other classes of genes: proliferation genes (cyclin D1 and c-MYC), immunity genes (chemokines, cytokines, antimicrobial peptides, adhesion molecules, iNOS, COX2) and negative feedback genes (IkBa, IkBb, A20) . (#6a; D4) Phosphorylation of p65RelA at Ser276 enhances its transcriptional activity due to strengthened interaction with the transcriptional coactivator CBP/p300 (Vermeulen et al., 2002) . (#7; C3): NF-kB function is primarily regulated by the inhibitory IkB family members (IkBa and IkBb), which bind NFkB and mask its NLS, thereby preventing nuclear uptake (Li and Stark, 2002) . (#8; C1): IkBa phosphorylation is a crucial step in the pathway leading to the activation of NFkB. It is catalysed by an IkBa kinase (IKK) consisting of IKK-a, IKK-b, and IKK-g (also called NEMO). Both IKK-a and IKK-b can directly phosphorylate IkBa and IkBb (Zandi et al., 1998) . Formation of active IKK requires homo-or heterodimerization of the catalytic subunits via their leucine zipper motifs (Zandi et al., 1997) . The activated IKK complex phosphorylates IkBa at Ser32 and Ser36. (#9; C2): Phosphorylation targets IkBa for ubiquitination and proteasome-mediated degradation. (#9a; C3): IkBa phosphorylation also inhibits the ability of IkBa to interact with NFkB and translocate to the nucleus. Substitution of any of the IkB's phosphorylation sites renders IkB's resistant to degradation (Karin and Ben-Neriah, 2000) . (#10; B2 and #11; A2) The IKK complex is activated by protein kinases including AKT, NIK or MEKK (Garg and Aggarwal, 2002) . IKK may also enhance its own activity by autophosphorylation (Karin and Ben-Neriah, 2000) . (#12; E3): Newly synthesized IkBa enters the nucleus in an energy-dependent process (Karin and Ben-Neriah, 2000) . (#13; E3): In the nucleus, IkBa binds NF-kB and displaces it from the DNA (Karin and Ben-Neriah, 2000) . (#14; D3): The nuclear export sequence (NES) on IkBa binds CRM1 (exportin 1) which mediates the export of IkBa : NF-kB from the nucleus into the cytosol (Sachdev et al., 1998) . (#15; E2 and #16, F3): In the nucleus, IkBb when not phosphorylated in its C-terminal region can bind NF-kB without displacing it from DNA. It may also prevent the displacement of NF-kB from DNA by IkBa. The action of NF-kB thus could be terminated by new synthesis of unphosphorylated IkBb. IkBb is constitutively phosphorylated in its C-terminus. C-terminal phosphorylation of IkBb prevents its interaction with NF-kB. NF-kB activation represents a paradigm for controlling the function of a regulatory protein via ubiquitination-dependent proteolysis, as an integral part of a phosphorylation-based signaling cascade (Karin and Ben-Neriah, 2000) . (#17: D5): NF-kB is inactivated during apoptosis by caspase-mediated cleavage of RelA, IkBa and IkBb ( 18; B2) Apoptosis defects and chemotherapy resistance Y Pommier et al phosphorylating IKKa on Thr23 (see the next section) (Ozes et al., 1999; Romashkova and Makarov, 1999) .
AKT deregulation in cancer
AKT is activated in a broad spectrum of cancers by two main mechanisms. First, AKT can be activated indirectly by PTEN inactivation. PTEN, the phosphatase that antagonizes PI3K, is genetically inactivated in more than 50% of melanomas and prostate cancers, 30-50% of glioblastomas and endometrial cancers, and 10% of breast cancers. Also, loss of PTEN can occur through transcriptional silencing or protein instability. The second main mechanism involved in AKT activation is directly due to AKT amplification, which has been reported in breast, ovarian and pancreatic cancers. Other mechanisms for elevated AKT activity in tumor cells include: (1) binding of AKT to the proto-oncogene TCL1 in T-cell leukemia; (2) overexpression of the catalytic (p110) subunit of PI3K and/or mutation/ inactivation of its regulatory (p85) subunit in some cases of ovarian cancers; and (3) constitutive activation of PI3K by oncogenes such as Ras (various cancers) and Bcr-Abl (chronic myelogenous leukemia) (Vivanco and Sawyers, 2002; Sordet et al., 2003; Wu et al., 2003) .
AKT-mediated resistance to chemotherapy
Several observations indicate that the cellular response to various chemotherapeutic drugs is dependent on the AKT-dependent survival pathway. Transfection of constitutively active AKT in lung cancer cells reduces topotecan-induced apoptosis (Nakashio et al., 2000) . Fibroblasts overexpressing AKT are resistant to staurosporine-and etoposide-induced apoptosis (Tang et al., 2001a; Karpinich et al., 2002) . PTEN-deficient tumor cell lines and tumors derived from PTEN-knockout mice displaying elevated AKT activity are resistant to apoptotic-inducing stimuli (Wu et al., 2003) . Conversely, inactivation of AKT by ectopic expression of PTEN in tumor cells enhances drug-induced apoptosis. Inactivation of AKT enhances the activity of the topoisomerase I inhibitor, SN-38 (Saga et al., 2002) , of the topoisomerase II inhibitors, doxorubicin (Huang et al., 2001) and etoposide (Yuan and Whang, 2002) , and of the protein kinase inhibitors, staurosporine and its derivative UCN-01 (Wan et al., 2002; Yuan and Whang, 2002) .
AKT as a target for cancer chemotherapy
AKT and PI3K inhibitors are rational therapeutic strategies for cancers with constitutively high activities of PI3K and/or AKT. Moreover, combination of specific PI3K and/or AKT inhibitors with existing chemotherapeutic drugs may act synergistically. There are presently no specific inhibitors of the PI3K/AKT survival pathways used clinically. In experimental systems, wortmannin and LY294002 inhibit both the PI3K/AKT pathway and other PI3K (e.g. ATM, ATR and DNA-PK). Recent observations indicate that the topoisomerase I inhibitor topotecan, UCN-01 and HSP90 inhibitors (e.g., geldanamycin, and radicicol derivatives) decrease AKT activity (Hill and Hemmings, 2002; Fujita and Tsuruo, 2003) . Topotecan inactivates AKT by suppressing the activity of the upstream kinases PI3K and PDK1 (Nakashio et al., 2000) . UCN-01 inhibits PDK1 (IC 50 o33 nM) without affecting PI3K (Sato et al., 2002a) . The HSP90 inhibitor geldanamycin (Figure 3a; F1) inhibits AKT by inactivating PDK1. Geldanamycin binds to the ATP binding site of HSP90 thereby inhibiting the chaperone activity of HSP90. It suppresses the PDK1-HSP90 binding (rather than the AKT-HSP90 binding) (Figure 3a; D2) , and causes the proteasome-dependent degradation of PDK1 (#24; D2-3) (Fujita et al., 2002) . The geldanamycin derivative 17-allylaminogeldanamycin (17-AAG) is currently in phase I clinical trial. The affinity of 17-AAG for HSP90 derived from tumor cells is 100-fold higher than for HSP90 from normal cells, which may explain the selectivity of HSP90 inhibitors for cancers (Kamal et al., 2003) . 17-AAG potentiates of UCN-01 the cytotoxicity in human leukemia cells . Thus, besides PI3K and AKT, PDK1 and PDK1-interacting proteins (e.g. HSP90 , PRK2 (Vanhaesebroeck and Alessi, 2000), 14-3-3 proteins (Sato et al., 2002b) , the proto-oncogene TCL1 (Kunstle et al., 2002) , CTMP (Maira et al., 2001) ) are promising new targets for tumors with enhanced AKT activity.
NF-kB
Nuclear factor of kB (NF-kB) is a family of closely related dimeric transcription factors that bind to the kB sites. They are the cellular homolog of the retroviral oncogene v-REL . The Rel/NF-kB family in mammals consists of five cellular proteins: p50/ p105 (NF-kB1), p52/p100 (NF-kB2), c-Rel, RelB and RelA (p65), which function as homo-or heterodimers (the p65/RelA and p50 heterodimer being the most prevalent). The p50 and p52 subunits of NF-kB1 and NF-kB2 are derived from proteolytic cleavage of the Cterminal domain from the p105 and p100 precursor molecules following monoubiquitination (Figure 4 ; #1; B4) . The p50 or p52 subunit then binds p65RelA, c-Rel, or RelB to form the active NF-kB complexes that can enter the nucleus (#4; D4) (except perhaps for those involving RelB) . In the nucleus, the NF-kB complexes bind to a set of related DNA target sites, collectively called kB sites (#5; F4) and stimulate the expression of genes suppressing apoptosis, promoting cell growth, stimulating immune responses and functioning in negative feedback (#6; F5) . The nuclear localization signal is contained in the Rel domains of the NF-kB molecules. The p65RelA subunit of the p65 : p50 heterodimer contains the transactivation domain. RelB (D6) lacks the transcription activation domain and therefore may compete to inhibit transcription (like a dominantnegative regulator).
In most resting cells, NF-kB is retained in the cytoplasm bound to the inhibitory proteins IkB's (IkBa, IkBb, IkBe, p105 and p100) (Figure 4 ; #7; C3). IkB binding obscures the NF-kB nuclear localization signal (NLS) and blocks NF-kB's ability to enter the nucleus (Winston et al., 1999; Habib et al., 2001) . In response to activators of the NF-kB pathway, such as TNFa, IkB is rapidly phosphorylated at Ser32 and Ser36 (Habib et al., 2001; by the IkB kinase (IKK), consisting of IKKa, IKKb, and IKKg/NEMO (#8; C1). Phosphorylated IkBa is degraded by the proteasome following ubiquitination (#9; C2) (Habib et al., 2001; . Mutations of either Ser32 or Ser36 (even to Thr) of IkBa impair its degradation (Kapahi et al., 2000) . In addition, phosphorylation of IkBa inhibits its binding to NF-kB complexes (#9a; C3) and impairs its ability to move to the nucleus (#9b; C3) (Kapahi et al., 2000) . Therefore, phosphorylation blocks the action of IkBa by parallel routes that all serve to trigger NF-kB activity. Additional pathways for IkBa removal (reviewed by Kapahi et al., 2000) involve phosphorylation of IkBa at Tyr42 in response to hypoxia by a Src-family tyrosine kinase, which dissociates IkBa from NF-kB without the involvement of proteasome-mediated degradation. In response to shortwave UV, IkBa may become targeted for proteasomal degradation without detectable phosphorylation.
In addition to keeping NF-kB in the cytoplasm, IkBa can function to export NF-kB from the nucleus. IkBa binds nuclear NF-kB, and the nuclear export sequence (NES) of IkBa mediates the cytosolic export of the IkBa : NF-kB complex (Figure 4 ; #14; D3) (ArenzanaSeisdedos et al., 1997; Sachdev et al., 1998) . This mechanism may play a major role for terminating NFkB activity. IkBb also enters the nucleus. However, it can bind NF-kB without displacing it from DNA (#16; F3). Therefore, IkBb may prevent the displacement of NF-kB from DNA by IkBa and could function to stabilize NF-kB activity (Kapahi et al., 2000) .
The kinase activity of IKK requires phosphorylation of its IKKa and IKKb subunits . AKT being one of the IKK kinases (Figures 3a and 4: #11; A1-3) (Ozes et al., 1999; Romashkova and Makarov, 1999) , NF-kB activation is one of the mechanisms by which AKT enhances cell survival (Madrid et al., 2001 ) (see Figure 3 and the previous section). Thus, the AKT and the NF-kB pathways are likely to work in concert.
Regulation of apoptosis by NF-kB NF-kB modulates the expression of many genes that control cell survival (Karin and Lin, 2002) . While some of the target genes products are protective and others death inducing, the primary role of NF-kB is to promote cell survival as massive apoptosis of liver cells is observed in embryonic NF-kB-knockout mice (Beg et al., 1995) . NF-kB mediates its antiapoptotic function by stimulating the expression of: (1) the inhibitors of apoptosis proteins (IAPs), which bind and inhibit caspases (Burks et al., 1998; Deveraux et al., 1998) , and of c-FLIP (FLICE (caspase-8)-inhibitory protein) which blocks caspase-8 activity (Micheau et al., 2001 );
(2) the Bcl-2 homologs A1/Bfl-1 (Budihardjo et al., 1999) , and Bcl-x L ; (3) the adaptor molecules (TRAF-1, TRAF-2) ; and (4) other molecules such as A20 (Krikos et al., 1992) , manganese superoxide dismutase (Manna et al., 1998) and IEX-1L (Hu et al., 1998) .
Paradoxically, NF-kB can also induce the transcription of proapoptotic molecules like FasL (CD95L) (Kasibhatla et al., 1999) , Fas (CD95) (Andjelkovic et al., 1999) , death receptor 6 (DR6) (Kasof et al., 2001) , DR4, DR5 (Antonsson et al., 2001) and IkBa (Bessho et al., 1994) . Post-translational modifications, such as acetylation and methylation of transcription factors or of the chromatin environment can also affect the NF-kB transcriptional activity (Vermeulen et al., 2002) . Recently, Wang et al. (2002) have suggested that a structural motif, called death domain (DD), present in one of the mammalian NF-kB proteins, NF-kB2/p100, allows it to directly activate cell death in a transcriptionindependent manner. It is also suggested that the loss of the proapoptotic function of NF-kB2/p100 is directly linked to its oncogenic activity in lymphomas (Hacker and Karin, 2002) . The tumor suppressor CYLD has been shown to regulate negatively NF-kB signaling by deubiquitination (Kovalenko et al., 2003) .
To terminate the antiapoptotic effect of NF-kB, several key components of the NF-kB pathway including NF-kB itself are targeted by caspases (Levkau et al., 1999) . Caspase-mediated cleavage of RelA (#17; D5) during apoptosis generates a RelA fragment that can bind DNA but is unable to activate transcription (Levkau et al., 1999) . Another NF-kB inhibitory mechanism is caspase-3-mediated cleavage of IkBa, (#18; A2), which creates a natural super-repressor form of IkBa that acts to facilitate apoptosis by constitutively inhibiting NF-kB (Reuther and Baldwin, 1999) . Caspases can also cleave and inactivate the IKKb catalytic subunit of the IKK complex (Tang et al., 2001b) . Two of the signaling proteins RIP (Hong et al., 2000) and TRAF2 (Arch et al., 2000) involved in NF-kB activation are also caspase substrates. Thus, the NF-kB pathway represents a dense interaction network (simplified in Figure 3a ) with a range of potential biological effects.
NF-kB deregulation in cancer
NF-kB activation probably acts in conjunction with other oncogenic mutations or DNA rearrangements to promote the development of lymphoid-, myeloid-and epithelial-derived (breast and gastrointestinal) cancers . The retroviral v-Rel oncogene causes aggressive lymphomas and leukemias in chicken. Inhibition of NF-kB by expression of the superrepressor IkBa (Baldwin, 2001) or by a dominantnegative form of IKK blocks focus formation induced by Ras (Arsura et al., 2000) . The oncogenic fusion protein BCR-ABL associated with chronic myelogenous leukemia activates NF-kB, and tumorigenesis driven by BCR-ABL can be blocked by expression of the super-repressor IkBa (Baldwin, 2001) . Chromosomal aberrations involving the human c-rel and NF-kB2 genes are found in many hematopoietic and solid tumors (reviewed in . NF-kB activation is observed in most breast cancer cells, although the exact mechanisms involved remain unknown . NF-kB is also activated in gastrointestinal cancers possibly as a result of the constitutive activation of upstream signaling kinases or mutations inactivating IkB.
NF-kB and chemoresistance
Cells that express constitutively activated NF-kB are resistant to various chemotherapeutic agents (reviewed in Paillard, 1999) . NF-kB is also activated by most chemotherapeutic agents including taxol, doxorubicin, daunorubicin, etoposide, vincristine, vinblastine, ara-C, anthralin, AZT, ciprofirate, cisplatin, haloperidol, methamphetamine, phenobarbital, tamoxifen and camptothecin (Pahl, 1999) . Enhanced NF-kB activity has been linked to decreased apoptosis via expression of the antiapoptotic genes described above and in Figure 4 (F5-6) (Budihardjo et al., 1999) and enhanced expression of the multiple-drug resistance (MDR) gene product (Zhou and Kuo, 1997; Antonsson et al., 2001) . NF-kB activation also plays an antiapoptotic role in human leukemic K562 cells exposed to ionizing radiation (Cataldi et al., 2003) . Wang et al. (1996) reported that apoptosis induced by daunorubicin is blocked by NF-kB. The same group later showed that camptothecin (CPT-11)-induced apoptosis is blocked by NF-kB . Conversely, NF-kB inhibition sensitizes retinoblastoma cells to doxorubicin (Poulaki et al., 2002) . Other reports indicate that NFkB activation blocks apoptosis induced by taxol but has no effect on apoptosis induced by doxorubicin, vincristine or vinblastine (Giri and Aggarwal, 1998; Ray et al., 1998) . Constitutive NF-kB activity confers resistance to gemcitabine in pancreatic carcinoma and against paclitaxel in prostate cancer (Flynn et al., 2003) .
Proapoptotic effects of NF-kB are also supported by pharmacological experiments. Etoposide-and ara Cmediated apoptosis have been shown to require NF-kB activation (Bessho et al., 1994; Marinovich et al., 1996; Usami et al., 1998) . The contradictory effects of NF-kB are probably cell type-specific and/or dependent on the inducing signal (i.e. the cell-and drug-specific networks). Nevertheless, in general, the activation of NFkB increases resistance to apoptosis ordinarily induced by chemotherapy or radiation therapy.
NF-kB as a target for cancer chemotherapy
Correlation between NF-kB expression, tumor formation and cellular resistance to chemotherapeutic drugs makes the inhibition of NF-kB a valid therapeutic approach (Beg and Baltimore, 1996) . Abrogation of the constitutively active NF-kB by dominant-negative super-repressor IkB mutant adenoviral construct enhances the apoptotic potentials of paclitaxel and rhTNF-a in the chemoresistant DU-145 prostate cancer cells (Flynn et al., 2003) and sensitivity to etoposide (VP-16) and doxorubicin in pancreatic carcinoma cells (Sato et al., 2003) . In melanoma, gene transfer has been used to inactivate RelA (McNulty et al., 2001) and overexpress the IkB inhibitors (Bakker et al., 1999; Huang and Strasser, 2000) . Recently, Stroh et al. (2003) have shown specific inhibition of NF-kB through intracellular protein delivery of IkBa by the herpesvirus protein VP22. However, the clinical feasibility of gene therapy approaches is currently limited by the requisite intratumoral delivery of the recombinant virus that expresses the NF-kB inhibitor.
Inhibition of NF-kB in association with chemotherapy strongly enhances the apoptotic potential of the chemotherapy. Inducible chemoresistance to CPT-11 (Cusack et al., 2000; Baldwin, 2001 ) and gemcitabine (Jones et al., 2000) can be overcome by transient inhibition of NF-kB through adenovirus-mediated expression of a degradation-resistant mutant of IkB. Treatment with CPT-11 in association with the proteasome inhibitor PS-341 also reduces tumor size (Cusack et al., 2001) . Disulfiram-mediated inhibition of NF-kB activity enhances the activity of 5-fluorouracil in human colorectal cancer cell lines (Ling et al., 2003) . The antiinflammatory drug sulfasalazine sensitizes pancreatic carcinoma cells to etoposide by inhibition of NF-kB . Combination of tumor necrosis factor-alpha with sulindac augments its apoptotic potential and suppresses tumor growth of human carcinoma cells in nude mice (Yasui et al., 2003) . These observations indicate that NF-kB plays an important role in chemoresistance and establishes NF-kB as a new adjuvant approach in chemotherapy.
Several strategies have been employed to block NFkB (reviewed in Garg and Aggarwal., 2002) . They involve: (a) blocking the proteasome degradation of IkB with proteasome inhibitors like Bortezomib (VELCADEt, formerly known as PS-341 (Cusack et al., 2001; Sunwoo et al., 2001; Cusack, 2003) ) and peptide aldehydes (Jobin et al., 1998) ; (b) blocking the phosphorylation of IkB by inhibiting IKK with nonsteroidal anti-inflamatory drugs such as aspirin (Frantz and O'Neill, 1995) , arsenic trioxide (Kapahi et al., 2000) , nitric oxide (Katsuyama et al., 1998) , or the retinoid antagonist MX781 (Bayon et al., 2003) ; (c) blocking nuclear translocation of NF-kB by cell-permeable peptides like SN-50 (Lin et al., 1995; Pieper and Riaz ul, 1997 ) that binds to the NF-kB NLS; (e) blocking the DNA binding of NF-kB by transcription factor decoy peptides (D'Acquisto et al., 2000) ; (f) antioxidants like curcumin (Singh and Aggarwal, 1995) , glutathione (Cho et al., 1998) and vitamin C (Staal et al., 1993) that block NF-kB activation; (g) genetic manipulations of proteins in the NF-kB activation pathway, like dominantnegative mutants of TRAF2 and TRAF6 that suppress NF-kB activity (Epinat and Gilmore, 1999) ; and (h) the NF-kB inhibition using recombinant adenovirusmediated overexpression of the IkBa gene (Bakker et al., 1999; Baldwin, 2001; McNulty et al., 2001) . Selective IKK inhibitors appear as the most promising and most advanced strategy (Karin et al., 2004) .
Global (and apparently paradoxical) changes in pathways: the 'permissive apoptosis-resistance' hypothesis In a study of gene expression changes associated with a drug-resistant cell line, conducted in our laboratory, we encountered a pattern of seemingly paradoxical changes consistent with the hypothesis that multidrug resistance could primarily involve the development of a defect in apoptosis (Reinhold et al., 2003) . The hypothesis, which we call 'permissive apoptosis resistance,' also entails gene expression changes that promote cell proliferation, but that would induce apoptosis were it not for a primary defect in this process.
The study compared a human prostate cancer cell line (DU145) with a subline that had been selected for resistance to a camptothecin. cDNA microarray analysis of 1648 cancer-related genes disclosed expression differences in 181 of these genes. Among these 181 genes, there was a larger than expected number of the apoptosisrelated genes, suggesting a general defect in the apoptosis machinery. Indeed, the resistant line displayed reduced apoptotic responses to several agents other than camptothecin, including cisplatin, staurosporine, UV, ionizing radiation, and serum deprivation. Closer examination of the gene expression changes, however, disclosed the surprising fact that many of the changes were in the wrong direction for apoptosis resistance.
In order to make sense of this surprising pattern, we charted the altered genes in a molecular interaction map. This diagram ( Figure 5 ) included color distinctions between proapoptotic versus antiapoptotic genes, and between genes altered in the 'expected' versus 'contrary' directions for apoptosis resistance in the drug-resistant cells. The color code is explained in the figure caption. What emerged is that almost all of the genes altered in the expected direction fell into one of two categories. Most were in the downstream core apoptosis network, including the genes BAD, caspase-6, and some associated genes, while some were regulators of the key survival kinase, AKT. On the other hand, nearly all of Figure 5 Molecular interaction map of the apoptosis-related pathways in which gene expression differences were observed (Reinhold et al., 2003) . The observed gene expression ratios are shown in brackets next to the molecular species names, and the numbers are highlighted purple when the expression differed by a factor of X1.5 in either direction. Where molecular species have been implicated in favoring or suppressing apoptosis, their symbols are bordered in red or green, respectively. When the mRNA expression changes were in the expected direction, the gene symbol is shaded yellow; when in the contrary direction, it is shaded blue the genes altered in the contrary direction were in pathways that impact both apoptosis and cell proliferation, including c-Myc, E2F1, and players in the NF-kB and TGFa pathways. The changes in the drug-resistant cells were nearly always such that they would be expected to enhance both apoptosis and cell proliferation.
These findings suggested a model ('permissive apoptosis resistance') as one route by which cells could acquire multidrug resistance. According to this model (Figure 6 ), cells would first be selected for one or more defects in the core apoptosis network, that is, in genes that function primarily to control or execute apoptosis. When this defect is in place, the cells would be free to acquire other gene expression changes that would enhance proliferation, but that would also have induced apoptosis were it not for the downstream defect.
Conclusions
Apoptosis is presently one of the most obvious targets for cancer treatment as its relatively common inactivation in tumors, contributes to carcinogenesis, as well as resistance to chemotherapy. The growing knowledge of the apoptotic pathways and the fact that a number of kinases, such as AKT, PI3K and IKK downregulate apoptosis specifically in tumors open new avenues for therapeutic approaches in the near future.
As knowledge of the apoptotic pathways and of their regulation increases, it is clear that the regulation of cellular pathways is seemingly complex. However, such knowledge is needed for identifying the most critical elements and the general rules driving molecular networks. Molecular interaction networks are generally multistep processes (for instance, see Figure 3 -5. for Bad inactivation by AKT). They tend to be robust with multiple ways to achieve the same functional goal (see Figure 3a for AKT activation). In that sense, they tend to be functionally relatively simple. Molecular interaction mapping is a first necessary step for computer simulations of cellular pathways (Kohn, 2001) . It is likely that general (and simplifying) rules will emerge (see Figure 6 ), and that we will be able to determine and use which among the many tumor parameters are critically needed to guide the prescription of a specific inhibitor of a given pathway. Figure 6 The 'permissive apoptosis-resistance' model for the selection of multidrug-resistant cells. Box A includes proteins that primarily affect apoptosis. Box B includes proteins that affect both apoptosis and cell proliferation, the effect on apoptosis being via proteins in Box A. Box A corresponds approximately to the righthand half of the molecular interaction map in Figure 5 , and Box B to the left hand. Growth in the presence of drug selects for cells that are apoptosis-resistant because of changes in the expression of proteins in Box A. When the route to apoptosis via Box A has been blocked, cells become free to acquire proliferative advantage by changes in the expression of proteins in Box B Apoptosis defects and chemotherapy resistance Y Pommier et al
